39039039DVT3004 A multicenter, randomized, placebo-controlled, pragmatic Phase 3 study investigating the efficacy and safety of rivaroxaban to reduce the risk of major venous and arterial thrombotic events, hospitalization and death in medically ill outpa

NCT04508023

A multicenter, randomized, placebo-controlled, pragmatic Phase 3 study investigating the efficacy and safety of rivaroxaban to reduce the risk of major venous and arterial thrombotic events, hospitalization and death in medically ill outpatients with acute, symptomatic COVID-19 infection

Principal Investigator

Sponsor

Janssen Research & Development

The purpose of this study is to see if the study drug, rivaroxaban, is safe and useful for reducing the risk of blood clots in subjects who are diagnosed with COVID-19 and who have additional conditions that increase their risk of developing blood clots or related issues.